Abstract
Drug-induced liver injury (DILI) is a major concern for drug developers, regulators and clinicians. It is triggered by drug and xenobiotic insults leading to liver impairment or damage, in the worst-case liver failure. In contrast to acute “intrinsic” hepatotoxicity, DILI typically manifests in a very small subset of the population under treatment with no clear dose relationship and inconsistent temporal patterns and is therefore termed an idiosyncratic event. Involved are multifactorial, compound-dependent mechanisms and host-specific factors, making the prediction in preclinical test systems very challenging. While preclinical safety studies in animals usually are able to capture direct, acute liver toxicities, they are less predictive for human DILI, where specific, human-derived in vitro models can potentially close the gap. On one hand, mechanistic approaches addressing key mechanisms involved in DILI in well-characterized and standardized in vitro test systems have been developed. On the other hand, co-cultures of different cell types, including patient- and/or stem cell-derived cells, in a three-dimensional setup allow for prolonged incubations and multiplexed readouts. Such complex setups might better reflect multifactorial human DILI. One major challenge is that for many compounds with human DILI the underlying mechanisms are not yet fully understood, complicating establishment and validation of predictive cellular tools. A tiered approach including rapid mechanism-based in vitro screens followed by confirmatory tests in more physiologically relevant models might allow minimizing DILI risk early on in vitro. Such complex, integrated approaches will gain from larger collaborations in multidisciplinary groups bringing existing knowledge and state-of-the-art technology together.
Similar content being viewed by others
References
Aleo MD, Luo Y, Swiss R, Bonin PD, Potter DM, Will Y (2014) Human drug-induced liver injury severity is highly associated to dual inhibition of liver mitochondrial function and bile salt export pump. Hepatology 60:1015–1022
Boelsterli UA, Lim PL (2007) Mitochondrial abnormalities–a link to idiosyncratic drug hepatotoxicity? Toxicol Appl Pharmacol 220:92–107
Brink A, Paehler A, Funk C, Schuler F, Schadt S (2016) Minimizing the risk of chemically reactive metabolite formation of new drug candidates: implications for preclinical drug design. Drug Discov Today (in press)
Chalasani NP, Hayashi PH, Bonkovsky HL, Navarro VJ, Lee WM, Fontana RJ (2014) ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 109:950–966
Chalhoub WM, Sliman KD, Arumuganathan M, Lewis JH (2014) Drug-induced liver injury: what was new in 2013? Expert Opin Drug Metab Toxicol 10:959–980
Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W (2011) FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 16:697–703
Chen M, Borlak J, Tong W (2013) High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 58:388–396
Chen M, Bisgin H, Tong L, Hong H, Fang H, Borlak J, Tong W (2014a) Toward predictive models for drug-induced liver injury in humans: are we there yet? Biomark Med 8:201–213
Chen M, Borlak J, Tong W (2014b) Predicting idiosyncratic drug-induced liver injury: some recent advances. Expert Rev Gastroenterol Hepatol 8:721–723
Chen M et al (2014c) A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the ‘rule-of-two’ model. Arch Toxicol 88:1439–1449
Chen M, Suzuki A, Borlak J, Andrade RJ, Lucena MI (2015) Drug-induced liver injury: interactions between drug properties and host factors. J Hepatol 63:503–514
Chen M, Suzuki A, Thakkar S, Yu K, Hu C, Tong W (2016) DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug Discov Today 21:648–653
Corsini A et al (2012) Current challenges and controversies in drug-induced liver injury Drug safety 35:1099–1117
Dambach DM, Andrews BA, Moulin F (2005) New technologies and screening strategies for hepatotoxicity: use of in vitro models. Toxicol Pathol 33:17–26. doi:10.1080/01926230590522284
Daveau M, Davrinche C, Julen N, Hiron M, Arnaud P, Lebreton JP (1988) The synthesis of human alpha-2-Hs glycoprotein is down-regulated by cytokines in hepatoma Hepg2 Cells. FEBS Lett 241:191–194. doi:10.1016/0014-5793(88)81059-7
Dawson S, Stahl S, Paul N, Barber J, Kenna JG (2012) In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 40:130–138
Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ (2001) The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69:223–231
Frampton JE (2011) Ambrisentan. Am J Cardiovasc Drugs 11:215–226
Fredriksson L et al (2014) Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFalpha-mediated hepatotoxicity. Toxicol Sci 140:144–159
Funk C, Pantze M, Scheuermann G, Jehle L, Ponelle C, Lazendic M, Gasser R (2001a) Troglitazone-induced intrahepatic cholestasis by an interference with the hepatobiliary export of bile acids in male and female rats. Correlation with the gender difference in troglitazone-sulfate formation and the inhibition of the canalicular bile salt export pump (Bsep) by troglitazone and troglitazone-sulfate. Toxicol 167:83–98
Funk C, Ponelle C, Scheuermann G, Pantze M (2001b) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity. In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 59:627–635
Garzel B, Yang H, Zhang L, Huang SM, Polli JE, Wang H (2014) The role of bile salt export pump gene repression in drug-induced cholestatic liver toxicity. Drug Metab Dispos 42:318–322
Godoy P et al (2013) Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. Arch Toxicol 87:1315–1530. doi:10.1007/s00204-013-1078-5
Gomez-Lechon MJ, Tolosa L (2016) Human hepatocytes derived from pluripotent stem cells: a promising cell model for drug hepatotoxicity screening. Arch Toxicol 90:2049–2061
Holt MP, Ju C (2010) Drug-induced liver injury. Handb Exp Pharmacol 196:3–27
Jiang J, Wolters JEJ, van Breda SG, Kleinjans JC, de Kok TM (2015) Development of novel tools for the in vitro investigation of drug-induced liver injury. Expert Opin Drug Metab Toxicol 11:1523–1537. doi:10.1517/17425255.2015.1065814
Kaplowitz N (2013) Avoiding idiosyncratic DILI: two is better than one. Hepatology 58:15–17
Khetani SR et al (2013) Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci 132:107–117
Kock K et al (2014) Risk factors for development of cholestatic drug-induced liver injury: inhibition of hepatic basolateral bile Acid transporters multidrug resistance-associated proteins 3 and 4. Drug Metab Dispos 42:665–674
Kostadinova R et al (2013) A long-term three dimensional liver co-culture system for improved prediction of clinically relevant drug-induced hepatotoxicity. Toxicol Appl Pharmacol 268:1–16
Krueger W, Boelsterli UA, Rasmussen TP (2014) Stem cell strategies to evaluate idiosyncratic drug-induced liver injury. J Clin Transl Hepatol 2:143–152
Kuijper IA, Yang H, Van de Water B, Beltman JB (2016) Unraveling cellular pathways contributing to drug-induced liver injury by dynamic modeling. Expert Opin Drug Metab Toxicol. doi:10.1080/17425255.2017.1234607
Leise MD, Poterucha JJ, Talwalkar JA (2014) Drug-Induced Liver Injury. Mayo Clin Proc 89:95–106. doi:10.1016/j.mayocp.2013.09.016
Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W (2011) Translating clinical findings into knowledge in drug safety evaluation–drug induced liver injury prediction system (DILIps). PLoS Comput Biol 7:e1002310
Marroquin LD, Hynes J, Dykens JA, Jamieson JD, Will Y (2007) Circumventing the crabtree effect: replacing media glucose with galactose increases susceptibility of hepG2 cells to mitochondrial toxicants. Toxicol Sci 97:539–547
Marx U et al (2016) Biology-inspired microphysiological system approaches to solve the prediction dilemma of substance testing. ALTEX 33:272–321. doi:10.14573/altex.1603161
McGill MR, Jaeschke H (2014) Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients. Expert Opin Drug Metab Toxicol 10:1005–1017
Meex SJR, Andreo U, Sparks JD, Fisher EA (2011) Huh-7 or HepG2 cells: which is the better model for studying human apolipoprotein-B100 assembly and secretion? J Lipid Res 52:152–158. doi:10.1194/jlr.D008888
Mesens N et al (2015) Are zebrafish larvae suitable for assessing the hepatotoxicity potential of drug candidates? J Appl Toxicol 35:1017–1029. doi:10.1002/jat.3091
Messner S, Agarkova I, Moritz W, Kelm JM (2013) Multi-cell type human liver microtissues for hepatotoxicity testing. Arch Toxicol 87:209–213. doi:10.1007/s00204-012-0968-2
Morgan RE et al (2013) A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicol Sci 136:216–241
Moulin F, Flint O (2015) In vitro models for the prediction of drug-induced liver injury in lead discovery. Antitargets and drug safety. Wiley-VCH Verlag GmbH & Co. KGaA, New York, pp 125–158
Mulliner D, Schmidt F, Stolte M, Spirkl H-P, Czich A, Amberg A (2016) Computational models for human and animal hepatotoxicity with a global application scope. Chem Res Toxicol 29:757–767. doi:10.1021/acs.chemrestox.5b00465
O’Brien PJ (2014) High-content analysis in toxicology: screening substances for human toxicity potential, elucidating subcellular mechanisms and in vivo use as translational safety biomarkers. Basic Clin Pharmacol 115:4–17. doi:10.1111/bcpt.12227
Olson H et al (2000) Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 32:56–67
Peters TS (2005) Do preclinical testing strategies help predict human hepatotoxic potentials? Toxicol Pathol 33:146–154
Poon KL et al (2016) Humanizing the zebrafish liver shifts drug metabolic profiles and improves pharmacokinetics of CYP3A4 substrates. Arch Toxicol. doi:10.1007/s00204-016-1789-5
Roth RA, Ganey PE (2010) Intrinsic versus Idiosyncratic drug-induced hepatotoxicity-two villains or one? J Pharmacol Exp Ther 332:692–697. doi:10.1124/jpet.109.162651
Roth A, Singer T (2014) The application of 3D cell models to support drug safety assessment: opportunities & challenges. Adv Drug Deliv Rev 69–70:179–189
Sakatis MZ et al (2012) Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chem Res Toxicol 25:2067–2082
Schadt S et al (2015) Minimizing DILI risk in drug discovery—a screening tool for drug candidates. Toxicol In Vitro 30:429–437
Shah F, Leung L, Barton HA, Will Y, Rodrigues AD, Greene N, Aleo MD (2015) Setting clinical exposure levels of concern for drug-induced liver injury (DILI) using mechanistic in vitro assays. Toxicol Sci 147:500–514. doi:10.1093/toxsci/kfv152
Shaw PJ, Ganey PE, Roth RA (2010) Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. Toxicol Sci 118:7–18
Siramshetty VB, Nickel J, Omieczynski C, Gohlke BO, Drwal MN, Preissner R (2016) WITHDRAWN—a resource for withdrawn and discontinued drugs. Nucleic Acids Res 44:D1080–1086. doi:10.1093/nar/gkv1192
Stepan AF, Walker DP, Bauman J, Price DA, Baillie TA, Kalgutkar AS, Aleo MD (2011) Structural alert/reactive metabolite concept as applied in medicinal chemistry to mitigate the risk of idiosyncratic drug toxicity: a perspective based on the critical examination of trends in the top 200 drugs marketed in the United States. Chem Res Toxicol 24:1345–1410. doi:10.1021/tx200168d
Swift B, Pfeifer ND, Brouwer KLR (2010) Sandwich-cultured hepatocytes: an in vitro model to evaluate hepatobiliary transporter-based drug interactions and hepatotoxicity. Drug Metab Rev 42:446–471. doi:10.3109/03602530903491881
Thompson RA et al (2012) In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 25:1616–1632. doi:10.1021/tx300091x
Thompson RA, Isin EM, Ogese MO, Mettetal JT, Williams DP (2016) Reactive Metabolites: current and emerging risk and hazard assessments. Chem Res Toxicol 29:505–533. doi:10.1021/acs.chemrestox.5b00410
Uetrecht JP (1999) New concepts in immunology relevant to idiosyncratic drug reactions: the “danger hypothesis” and innate immune system. Chem Res Toxicol 12:387–395
Vliegenthart ADB, Tucker CS, Del Pozo J, Dear JW (2014) Zebrafish as model organisms for studying drug-induced liver injury. Brit J Clin Pharmaco 78:1217–1227. doi:10.1111/bcp.12408
Ware BR, Khetani SR (2016) Engineered liver platforms for different phases of drug development. Trends Biotechnol (in press)
Ware BR, Berger DR, Khetani SR (2015) Prediction of drug-induced liver injury in micropatterned co-cultures containing iPSC-derived human hepatocytes. Toxicol Sci 145:252–262. doi:10.1093/toxsci/kfv048
Watkins P (2015) The dili-sim initiative, Integrated systems pharmacology modeling to explain and predict drug hepatotoxicity. Clin Therap 37:e170
Wu Y, Geng XC, Wang JF, Miao YF, Lu YL, Li B (2016) The HepaRG cell line, a superior in vitro model to L-02, HepG2 and hiHeps cell lines for assessing drug-induced liver injury. Cell Biol Toxicol 32:37–59. doi:10.1007/s10565-016-9316-2
Xu JHJ, Henstock PV, Dunn MC, Smith AR, Chabot JR, de Graaf D (2008) Cellular imaging predictions of clinical drug-induced liver injury. Toxicol Sci 105:97–105. doi:10.1093/toxsci/kfn109
Yuan L, Kaplowitz N (2013) Mechanisms of drug-induced liver injury. Clin Liver Dis 17:507–518. doi:10.1016/j.cld.2013.07.002
Zhang J, Doshi U, Suzuki A, Chang CW, Borlak J, Li AP, Tong W (2016) Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: results from 152 marketed drugs with known liver injury profiles. Chem Biol Interact 255:3–11
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Funk, C., Roth, A. Current limitations and future opportunities for prediction of DILI from in vitro. Arch Toxicol 91, 131–142 (2017). https://doi.org/10.1007/s00204-016-1874-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00204-016-1874-9